Form 4 for BBIO BridgeBio Pharma, Inc.
Accepted 2025-08-07 00:00:00 ET · period of report 2025-08-05 · accession 0000950170-25-105185 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-08-07 | 2025-08-05 | BBIO | Ellis Andrea | Dir | M - OptEx | $16.75 | +17.2K | 35.8K | +92% | +$287.5K |
| DT | 2025-08-07 | 2025-08-05 | BBIO | Ellis Andrea | Dir | S - Sale+OE | $49.00 | -17.2K | 18.6K | -48% | -$841.2K |
| DT | 2025-08-07 | 2025-08-05 | BBIO | Ellis Andrea | Dir | M - OptEx | $0.00 | -17.2K | 34.3K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-05 | M | A | 17,167 | $16.75 | 35,756 | D | — | — | |
| 2 | Common | Common Stock | 2025-08-05 | S | D | 17,167 | $49.00 | 18,589 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2025-08-05 | M | D | 17,167 | $0.00 | 34,334 | D | $16.75 · — to 2033-06-21 | 17,167 Common Stock | (F2) The option vests in three annual installments from June 21, 2024 through June 21, 2026, subject to the Reporting Person's continued service on the Issuer's board of directors. |